Literature DB >> 23772616

HIV-associated chronic immune activation.

Mirko Paiardini1, Michaela Müller-Trutwin.   

Abstract

Systemic chronic immune activation is considered today as the driving force of CD4(+) T-cell depletion and acquired immunodeficiency syndrome (AIDS). A residual chronic immune activation persists even in HIV-infected patients in which viral replication is successfully inhibited by anti-retroviral therapy, with the extent of this residual immune activation being associated with CD4(+) T-cell loss. Unfortunately, the causal link between chronic immune activation and CD4(+) T-cell loss has not been formally established. This article provides first a brief historical overview on how the perception of the causative role of immune activation has changed over the years and lists the different kinds of immune activation characteristic of human immunodeficiency virus (HIV) infection. The mechanisms proposed to explain the chronic immune activation are multiple and are enumerated here, as well as the mechanisms proposed on how chronic immune activation could lead to AIDS. In addition, we summarize the lessons learned from natural hosts that know how to 'show AIDS the door', and discuss how these studies informed the design of novel immune modulatory interventions that are currently being tested. Finally, we review the current approaches aimed at targeting chronic immune activation and evoke future perspectives.
© 2013 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23772616      PMCID: PMC3729961          DOI: 10.1111/imr.12079

Source DB:  PubMed          Journal:  Immunol Rev        ISSN: 0105-2896            Impact factor:   12.988


  200 in total

Review 1.  Neopterin as a marker for activated cell-mediated immunity: application in HIV infection.

Authors:  D Fuchs; A Hausen; G Reibnegger; E R Werner; M P Dierich; H Wachter
Journal:  Immunol Today       Date:  1988-05

2.  Production of interleukins in human immunodeficiency virus-1-replicating lymph nodes.

Authors:  D Emilie; M Peuchmaur; M C Maillot; M C Crevon; N Brousse; J F Delfraissy; J Dormont; P Galanaud
Journal:  J Clin Invest       Date:  1990-07       Impact factor: 14.808

3.  Production of tumor necrosis factor alpha and interleukin 1 beta by monocytic cells infected with human immunodeficiency virus.

Authors:  J M Molina; D T Scadden; R Byrn; C A Dinarello; J E Groopman
Journal:  J Clin Invest       Date:  1989-09       Impact factor: 14.808

4.  Use of infliximab to treat psoriatic arthritis in HIV-positive patients.

Authors:  Jérémie Sellam; Béatrice Bouvard; Charles Masson; Mickael Rousière; Caroline Villoutreix; Karine Lacombe; Vanessa Khanine; Jean-Marie Chennebault; Christian Leclech; Maurice Audran; Francis Berenbaum
Journal:  Joint Bone Spine       Date:  2007-01-31       Impact factor: 4.929

5.  Cyclosporin A specifically inhibits function of nuclear proteins involved in T cell activation.

Authors:  E A Emmel; C L Verweij; D B Durand; K M Higgins; E Lacy; G R Crabtree
Journal:  Science       Date:  1989-12-22       Impact factor: 47.728

6.  Slow disease progression and robust therapy-mediated CD4+ T-cell recovery are associated with efficient thymopoiesis during HIV-1 infection.

Authors:  Marie-Lise Dion; Rebeka Bordi; Joumana Zeidan; Robert Asaad; Mohammed-Rachid Boulassel; Jean-Pierre Routy; Micheal M Lederman; Rafick-Pierre Sekaly; Remi Cheynier
Journal:  Blood       Date:  2007-04-01       Impact factor: 22.113

7.  AIDS as immune system activation: a model for pathogenesis.

Authors:  M S Ascher; H W Sheppard
Journal:  Clin Exp Immunol       Date:  1988-08       Impact factor: 4.330

8.  Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS).

Authors:  F Barré-Sinoussi; J C Chermann; F Rey; M T Nugeyre; S Chamaret; J Gruest; C Dauguet; C Axler-Blin; F Vézinet-Brun; C Rouzioux; W Rozenbaum; L Montagnier
Journal:  Science       Date:  1983-05-20       Impact factor: 47.728

9.  T-cell subset alterations in HIV-infected homosexual men: NIAID Multicenter AIDS cohort study.

Authors:  J V Giorgi; R Detels
Journal:  Clin Immunol Immunopathol       Date:  1989-07

10.  CD4+ T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract.

Authors:  Jason M Brenchley; Timothy W Schacker; Laura E Ruff; David A Price; Jodie H Taylor; Gregory J Beilman; Phuong L Nguyen; Alexander Khoruts; Matthew Larson; Ashley T Haase; Daniel C Douek
Journal:  J Exp Med       Date:  2004-09-13       Impact factor: 14.307

View more
  173 in total

1.  TLR7 dosage polymorphism shapes interferogenesis and HIV-1 acute viremia in women.

Authors:  Pascal Azar; José Enrique Mejía; Claire Cenac; Arnoo Shaiykova; Ali Youness; Sophie Laffont; Asma Essat; Jacques Izopet; Caroline Passaes; Michaela Müller-Trutwin; Pierre Delobel; Laurence Meyer; Jean-Charles Guéry
Journal:  JCI Insight       Date:  2020-06-18

2.  Vpr Enhances Tumor Necrosis Factor Production by HIV-1-Infected T Cells.

Authors:  Ferdinand Roesch; Léa Richard; Réjane Rua; Françoise Porrot; Nicoletta Casartelli; Olivier Schwartz
Journal:  J Virol       Date:  2015-09-23       Impact factor: 5.103

3.  Association between latent proviral characteristics and immune activation in antiretrovirus-treated human immunodeficiency virus type 1-infected adults.

Authors:  Emily C Liang; Lindsay Sceats; Nicholas L Bayless; Dara M Strauss-Albee; Jessica Kubo; Philip M Grant; David Furman; Manisha Desai; David A Katzenstein; Mark M Davis; Andrew R Zolopa; Catherine A Blish
Journal:  J Virol       Date:  2014-05-21       Impact factor: 5.103

4.  Antiretroviral Therapy in Simian Immunodeficiency Virus-Infected Sooty Mangabeys: Implications for AIDS Pathogenesis.

Authors:  Francesca Calascibetta; Luca Micci; Diane Carnathan; Benton Lawson; Thomas H Vanderford; Steven E Bosinger; Kirk Easley; Ann Chahroudi; Joseph Mackel; Brandon F Keele; Samuel Long; Jeffrey Lifson; Mirko Paiardini; Guido Silvestri
Journal:  J Virol       Date:  2016-07-27       Impact factor: 5.103

5.  High-fat diet induced central adiposity (visceral fat) is associated with increased fibrosis and decreased immune cellularity of the mesenteric lymph node in mice.

Authors:  Aaron M Magnuson; Daniel P Regan; Andrea D Booth; Josephine K Fouts; Claudia M Solt; Jessica L Hill; Steve W Dow; Michelle T Foster
Journal:  Eur J Nutr       Date:  2019-06-04       Impact factor: 5.614

6.  SLAMF7 Is a Critical Negative Regulator of IFN-α-Mediated CXCL10 Production in Chronic HIV Infection.

Authors:  Patrick O'Connell; Yuliya Pepelyayeva; Maja K Blake; Sean Hyslop; Robert B Crawford; Michael D Rizzo; Cristiane Pereira-Hicks; Sarah Godbehere; Linda Dale; Peter Gulick; Norbert E Kaminski; Andrea Amalfitano; Yasser A Aldhamen
Journal:  J Immunol       Date:  2018-12-10       Impact factor: 5.422

7.  Type I interferons suppress viral replication but contribute to T cell depletion and dysfunction during chronic HIV-1 infection.

Authors:  Liang Cheng; Haisheng Yu; Guangming Li; Feng Li; Jianping Ma; Jingyun Li; Liqun Chi; Liguo Zhang; Lishan Su
Journal:  JCI Insight       Date:  2017-06-15

8.  Kaposi's Sarcoma-Associated Herpesvirus Latency Locus Renders B Cells Hyperresponsive to Secondary Infections.

Authors:  Sang-Hoon Sin; Anthony B Eason; Rachele Bigi; Yongbaek Kim; SunAh Kang; Kelly Tan; Tischan A Seltzer; Raman Venkataramanan; Hyowon An; Dirk P Dittmer
Journal:  J Virol       Date:  2018-09-12       Impact factor: 5.103

9.  Differences by HIV serostatus in coronary artery disease severity and likelihood of percutaneous coronary intervention following stress testing.

Authors:  Matthew J Feinstein; Brian Poole; Pedro Engel Gonzalez; Anna E Pawlowski; Daniel Schneider; Tim S Provias; Frank J Palella; Chad J Achenbach; Donald M Lloyd-Jones
Journal:  J Nucl Cardiol       Date:  2016-10-13       Impact factor: 5.952

10.  The mixed lineage kinase-3 inhibitor URMC-099 improves therapeutic outcomes for long-acting antiretroviral therapy.

Authors:  Gang Zhang; Dongwei Guo; Prasanta K Dash; Mariluz Araínga; Jayme L Wiederin; Nicole A Haverland; Jaclyn Knibbe-Hollinger; Andrea Martinez-Skinner; Pawel Ciborowski; Val S Goodfellow; Tadeusz A Wysocki; Beata J Wysocki; Larisa Y Poluektova; Xin-Ming Liu; JoEllyn M McMillan; Santhi Gorantla; Harris A Gelbard; Howard E Gendelman
Journal:  Nanomedicine       Date:  2015-10-22       Impact factor: 5.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.